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Abstract
Background:  Antisense-mediated exon skipping is currently one of the most promising
therapeutic approaches for Duchenne muscular dystrophy (DMD). Using antisense
oligonucleotides (AONs) targeting specific exons the DMD reading frame is restored and partially
functional dystrophins are produced. Following proof of concept in cultured muscle cells from
patients with various deletions and point mutations, we now focus on single and multiple exon
duplications. These mutations are in principle ideal targets for this approach since the specific
skipping of duplicated exons would generate original, full-length transcripts.
Methods: Cultured muscle cells from DMD patients carrying duplications were transfected with
AONs targeting the duplicated exons, and the dystrophin RNA and protein were analyzed.
Results:  For two brothers with an exon 44 duplication, skipping was, even at suboptimal
transfection conditions, so efficient that both exons 44 were skipped, thus generating, once more,
an out-of-frame transcript. In such cases, one may resort to multi-exon skipping to restore the
reading frame, as is shown here by inducing skipping of exon 43 and both exons 44. By contrast, in
cells from a patient with an exon 45 duplication we were able to induce single exon 45 skipping,
which allowed restoration of wild type dystrophin. The correction of a larger duplication (involving
exons 52 to 62), by combinations of AONs targeting the outer exons, appeared problematic due
to inefficient skipping and mistargeting of original instead of duplicated exons.
Conclusion: The correction of DMD duplications by exon skipping depends on the specific exons
targeted. Its options vary from the ideal one, restoring for the first time the true, wild type
dystrophin, to requiring more 'classical' skipping strategies, while the correction of multi-exon
deletions may need the design of tailored approaches.
Background
Duchenne and Becker muscular dystrophy (DMD and
BMD, respectively) are allelic disorders caused by muta-
tions in the DMD gene, which codes for dystrophin [1,2].
Duchenne patients are diagnosed at a young age, suffer
from rapid and progressive loss of muscle function and
mostly die before the age of 30 due to respiratory or heart
failure [3]. By contrast, Becker patients are diagnosed at a
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later age, often remain ambulant until later in life and
generally have near normal life expectancies, although
more severe cases are known as well [3]. This discrepancy
can be explained by the type of mutation: out-of-frame
mutations lead to prematurely truncated, non-functional
dystrophin proteins and are associated with the severe
DMD phenotype, whereas in-frame mutations give rise to
internally deleted, but largely functional proteins found
in BMD patients [4]. Over 70% of all DMD and BMD
patients carry deletions of one or more exons; small muta-
tions resulting in premature stop codons or disrupted
splice sites are found in circa 20% of patients, while dupli-
cations of one or more exons make up for around 7% of
mutations [5].
During the last few years, promising results have been
obtained with antisense-mediated restoration of the read-
ing frame as a therapy for Duchenne patients [6-9]. This
strategy aims to correct the reading frame by inducing the
skipping of specific exons during pre-mRNA splicing,
using antisense oligonucleotides (AONs) that interfere
with the splicing of the targeted exons. Thus, a Becker-like
dystrophin can be introduced and a severe Duchenne con-
verted into a milder Becker phenotype. We have previ-
ously shown the applicability of this therapy in cultured
muscle cells derived from patients carrying different dele-
tions and point mutations [6,7,10].
Whereas single exon skipping would in theory offer a ther-
apy for over 50% of DMD patients, we have recently
shown the feasibility of the induced co-skipping of two or
even multiple exons: by targeting the two outer exons of a
stretch of exons, we were able to induce multiexon 45 to
51 skipping both in wild type and patient cell cultures.
[7]. This type of multiexon skipping further increases the
applicability of the exon skipping therapy to over 70%.
The therapeutic possibilities of deploying multiexon skip-
ping to create large deletions associated with mild pheno-
types are obvious [7,11]. However, we have recently
reported that there are significant technical limitations
that depend on the targeted stretch of exons, and the
length of the flanking introns [12].
There is one class of mutations, i.e. the duplication of one
or more exons, for which therapeutic antisense-induced
exon skipping has not yet been demonstrated. These
mutations would actually be ideal targets since the skip-
ping of the duplicated exon(s) would restore normal tran-
scripts allowing the synthesis of full-length, wild type
dystrophins (see Figures 1A, 3A and 4). In this study we
therefore focussed on antisense-induced exon skipping in
cultured cells from patients with two different single exon




AONs (h44AON1, h44AON2, h45AON5, h52AON1 and
h62AON1) have been described [13], and consist of 2'-O-
methyl RNA and full length phosphorothioate backbones
(Eurogentec, Belgium). Primers for RT-PCR were chosen
in flanking exons (Eurogentec, Belgium) (see Table 1,
sequences upon request).
Myoblast cultures and AON transfection
A primary myoblast culture derived from a DMD patient
carrying an exon 45 duplication was provided by Dr.
Francesco Muntoni (Imperial college, London, UK) and
was cultured as described elsewhere [14]. Myotubes were
obtained after 7–14 days of serum deprivation. Fibrob-
lasts (gift from Dr René de Coo, Erasmus Medical Center,
Rotterdam, the Netherlands) and amnioblasts (gift from
Dr Ieke Ginjaar, Leiden University Medical Center, Lei-
den, the Netherlands) were available for the patients with
an exon 44 duplication and an exon 52–62 duplication,
respectively. Following infection with an adenoviral vec-
tor containing the MyoD gene (Ad50MyoD; Crucell B.V.,
Leiden, the Netherlands) using a multiplicity of infection
(MOI) of 50–75, cells were forced into myogenesis,
according to standardized protocols [15-17]. Myotube
cultures were transfected with mixtures of 100 nM of each
AON (total AON concentration 100 nM for single and
200 nM for double targeting). Concentration series
ranged from 50–250 nM. Polyethylenemine (PEI) was
used as transfection reagent to enhance AON transfection
in vitro, according to the manufacturer's instructions
(ExGen 500, Fermentas), with 2.5 μl PEI applied per μg of
transfected AON.
RNA isolation and RT-PCR analysis
RNA was isolated 24–48 hours after transfection using
RNA-Bee according to manufacturer's instructions (Cam-
pro Scientific). A specific primed RT was performed using
the Transcriptor Reverse Transcriptase enzyme (Roche
Diagnostics) for 35 minutes at 55°C and 5 minutes at
85°C on ~1 μg of total RNA. PCR analysis was done as
described [6]. Skip fragments were isolated from gels and
their identity was confirmed with direct sequencing as
described [6].
Dystrophin analysis
Protein samples were isolated 2–8 days after treatment.
Non treated control samples were isolated at the same
time as the first treated sample. Immunohistochemical
and Western blot analyses were performed as previously
described [6]. Myosin polyclonal antibody L53 (a gift
from Dr. M. van den Hoff, Amsterdam Medical Center,
The Netherlands) was used to detect myosin, and
MANDYS1 (a gift from Dr. G. Morris, North East Wales
Institue, United Kingdom) and NCL-DYS2 (NovacastraBMC Medical Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2350/8/43
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Laboratories) were used to detect dystrophin for immuno-
histochemical analysis. For Western blot analysis NCL-
DYS1 (Novocastra Laboratories) was used to detect dys-
trophin and MF20 (Developmental Studies Hybridoma
Bank (University of Iowa, Iowa City)) to detect myosin.
Dystrophin intensities were determined with the Odyssey
software (Li-Cor, NE, USA).
Results
Exon 45 duplication
Myotube cultures from a patient with a duplication of
exon 45 (Figure 1A) were treated with an exon 45 specific
AON. RNA was isolated 2 days after transfection and RT-
PCR analysis revealed single exon 45 skipping at signifi-
cant levels (Figure 1B). Low levels of double exon 45 skip-
ping were observed in both treated and non treated
myotubes, which did not increase at higher AON concen-
trations (Figure 2). Protein samples were collected before,
2 and 5 days after treatment and analyzed by Western
blotting using the Dy4 antibody. Clear dystrophin signals
were detected in the treated samples (5% and 8% of wild
type levels after 2 and 5 days, respectively), whereas no
dystrophin was observed in the untreated sample (Figure
1C). The new dystrophin expression was confirmed by
immuno-histochemical analysis, where over 80% of
treated myotubes was dystrophin-positive (Figure 1D).
This is in fact the first time that a wild type dystrophin is
generated upon AON treatment. Note that in the non-
treated sample low levels of a transcript fragment with
similar length of those seen after single exon 45 skipping
were observed (Figure 1B, Figure 2 upper panel). This can
be explained by PCR artefacts; due to the duplication, the
first exon 45 of one PCR strand can anneal to the second
exon 45 of the other PCR strand, which would generate a
Exon skipping in myotube cultures derived from an exon 45 duplicated patient Figure 1
Exon skipping in myotube cultures derived from an exon 45 duplicated patient. A. Schematic overview of the mutation. Origi-
nal and duplicated exons are shown in blue and red, respectively. Restoration of the wild type transcript can be achieved by 
skipping of either the original or mutated exon 45 (upper panel) but skipping of both exons 45 results in an out-of-frame tran-
script (lower panel). B. RT-PCR analysis. Low levels of single exon 45 skipping can be seen in the non treated sample (NT). 
Exon 45 skipping levels increased significantly after treatment with an exon 45 specific AON (45). Double exon 45 skipping 
could occasionally be observed at low levels before and after AON treatment. In-frame and out-of-frame transcripts are 
depicted in green and red, respectively. Duplicated exons are shaded blue. M is 100 bp size standard, C is normal control, -RT 
is negative control. C. Western blot analysis. Clear dystrophin (Dy4) signals were detected 2 and 5 days (2d and 5d, respec-
tively) after AON treatment, whereas no dystrophin was observed in the non treated sample (NT). The control sample (HC) 
was diluted 10 times to prevent overexposure. Myosin staining (MF20) was used to confirm equal sample loading (myo). D. 
Immuno-histochemical analysis. No dystrophin signal was detected in non-treated myosin positive myotubes with either the 
Dy8 (data not shown) or the MANDYS1 antibodies (NT). After AON treatment (45AON), over 80% of myosin positive cells 
stained positive for dystrophin (dy8, data not shown, and MANDYS1).BMC Medical Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2350/8/43
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'wild type-like' product upon amplification. Correspond-
ing to this explanation, we confirmed that no dystrophin
protein was detected in the non treated cells by Western
blot and immuno-histochemical analyses.
Exon 44 duplication
The second single exon duplication that we studied for
antisense-induced exon skipping involves exon 44 (Figure
3A). In our experience exon 44 skipping is relatively easy,
and we have identified various efficient AONs [13]. Myo-
tube cultures from two brothers, both carrying an exon 44
duplication, were treated with these different exon 44 spe-
cific AONs. Exon 44 skipping was so efficient that in the
vast majority of transcripts both exons 44 were skipped
(Figure 3B). In order to enhance single exon 44 skipping
we performed a concentration series, used a shorter sub-
optimal AON (15mer instead of 20mer) and tested differ-
ent AON:PEI ratios (Figure 2 and data not shown). As for
the exon 45 duplication, wild type-like transcripts were
observed for each sample at varying levels (Figure 2).
Unfortunately, no dystrophin was detected using these
lower concentrations, not even for the concentration of 20
nM that appears to induce single exon 44 skipping. This
suggests that the different levels of wild type transcripts
reflect different levels of the PCR artefact. This is under-
lined by the finding that at effective concentrations (100
nM and up), the amount of the original duplicated tran-
script decreases, while the amount of double skipped tran-
scripts increases. These double skipped transcripts
generate mainly out-of-frame transcripts (Figure 3A) and
no dystrophin was thus introduced (data not shown).
There is another strategy to restore the reading frame for
these patients. We aimed at inducing the combined skip-
ping of exon 43 in addition to both exons 44 (Figure 3A,
third panel). Using a combination of exon 43 and 44 spe-
cific AONs, exon 42 was indeed spliced to exon 45 (exon
43-44-44 skip), which leads to an in-frame transcript.
Western blot analysis revealed a clear dystrophin signal
after treatment with exon 43 and 44 AONs, at 3% of wild
type levels (Figure 3C). In addition, dystrophin signals
were detected in over 70% of treated myotubes by
immuno-histochemical analysis, whereas none of the
myotubes stained positive for dystrophin without treat-
ment (Figure 3CD).
Exon 52–62 duplication
We have previously described a patient who carries an
exon 52–62 duplication, located between exons 63 and
64 [18]. As shown in the upper panel of Figure 4, multi-
exon skipping of the duplicated exons 52–62 would
restore the wild type transcript for this patient. Alterna-
tively, the reading frame can be restored to generate a
modified, in-frame duplication. This can be achieved
either by double exon skipping of the duplicated exons 52
and 62, or by multiexon skipping of the original exons 62,
63 and the duplicated exons 52 and 62 (Figure 4 middle
panel). Skipping of the original exon 52 and/or exon 62
or the original exons 52 through 62 will generate out-of-
frame transcripts (lower panel Figure 4).
As we have shown previously, it is possible to induce the
skipping of multiple exons using AONs targeting the outer
exons [7]. Indeed, after treatment of control myotube cul-
tures with AONs specific for exon 52 and exon 62, skip-
ping of the stretch of exons between exons 52 and 62 was
observed occasionally (twice in 18 samples), showing that
this multiexon skipping is, at least in principle, feasible
(data not shown). This multiexon skipping was not
detected is untreated control samples (n = 10) nor were
intermediate products, arising from the skipping of exons
within the targeted region, observed in treated or
Concentration series of exon 44 and exon 45 AONs Figure 2
Concentration series of exon 44 and exon 45 AONs. At a 
concentration of 100 nM (100) and up, levels of wild type 
transcript increased for the exon 45 duplicated patient 
(upper panel) compared to the untreated (NT) and 50 nM 
(50) treated samples. Double exon 45 skipping at low levels 
was observed for all samples. These levels increase slightly at 
100 nM and higher but do not increase further at higher con-
centrations. For the exon 44 duplicated patient (lower 
panel), variable low levels of wild type transcripts are present 
in each sample with the regular exon 44 AON and a short 
suboptimal AON (short), but as dystrophin was not restored 
this probably reflects fluctuating levels of the wild type-like 
artefact. At concentrations that are generally effective (100 
nM and up), the levels of original transcript decrease and the 
amount of double exon 44 skipped transcript increases. M is 
100 bp DNA marker, HC is healthy control.BMC Medical Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2350/8/43
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untreated samples. We then treated myotube cultures of
the patient with the exon 52 and exon 62 AONs and RNA
was analyzed by RT-PCR using primer pairs flanking the
duplication breakpoints and the original exons (Figure
5A–F). For both exon 52 and exon 62, skipping of the
original as well as the duplicated exons was observed (Fig-
ure 5A–E). However, the reading frame is restored only by
the combined skipping of the duplicated exons 52 and 62
in a transcript where the original exons 52 and 62 are
maintained. To verify this, one would have to analyze a
stretch of exons including the original exons 51 to 63, the
duplicated exons 52 to 62 and the original exon 64, which
is a fragment of over 4 kb in length. This was attempted
without success, so we aimed at amplification across the
duplication in order to see a decrease in duplicated tran-
scripts after AON treatment (Figure 5F). Unexpectedly,
equal levels of correctly spliced exon 63 were observed in
both untreated and treated patient myotubes. However,
these levels were lower than those observed for the control
myotube cultures. Unfortunately, we did not observe the
Exon skipping in myotube cultures derived from an exon 44 duplicated patient Figure 3
Exon skipping in myotube cultures derived from an exon 44 duplicated patient. A. Schematic overview of the mutation. Origi-
nal and duplicated exons are shown in blue and red, respectively. Restoration of the normal transcript can be achieved by skip-
ping of either the original or mutated exon 44 (upper panel) but skipping of both exons 44 results in out-of-frame transcripts 
(middle panel). Skipping exon 43 and both exons 44 will restore the reading frame (lower panel). B. RT-PCR analysis. Low lev-
els of single exon 44 skipping were observed in the non treated sample (NT). After treatment with exon 44 specific AONs (44) 
both copies of exon 44 were skipped in the majority of the transcripts, generating an out-of-frame product. Using a combina-
tion of AONs targeting exon 43 and 44 (43, 44) it was feasible to induce an in-frame transcript where exon 43 is skipped in 
addition to both copies of exon 44. In-frame and out-of-frame transcripts are depicted in green and red, respectively. Dupli-
cated exons are shaded in blue. M is 100 bp size standard, -RT is negative control. C. Western blot analysis. Dystrophin signals 
were detected in protein isolated 2 and 5 days (2d and 5d) after AON treatment and not in an untreated sample (NT). The 
control sample (HC) was diluted 10 times to prevent overexposure. Myosin staining was used to confirm equal sample loading 
(myo). D. Immuno-histochemical analysis. No dystrophin signal was detected in non-treated myosin-positive myotubes with 
either the Dy8 (data not shown) or the MANDYS1 antibody. After AON treatment over 70% of myosin positive cells stained 
positive for dystrophin as detected with Dy8 (data not shown) and MANDYS1.BMC Medical Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2350/8/43
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~1900 bp fragment containing the duplication in treated
or non treated RNA from the patient. On the basis of our
RT-PCR data we could thus not conclude whether the wild
type transcript or the reading frame was restored. There-
fore, Western blot analysis was used to detect restoration
of the dystrophin synthesis (Figure 5G). No dystrophin
was detected for up to 8 days after treatment, or in
untreated myotubes. Antibodies against myosin were
used to confirm that the differentiation of the myotubes
was sufficient to allow dystrophin synthesis.
Discussion
In principle, duplications are ideal targets for the exon
skipping therapy, as normal transcripts and wild type dys-
trophin are generated after AON treatment. In addition,
we hypothesized that for single exon duplications, exon
skipping might be more efficient per se, as skipping of
either one of the duplicated exons will restore the tran-
script. This indeed turned out to be feasible for an exon 45
duplication patient. Thus, in this case we achieved the
ideal therapeutic result: patient myotubes producing wild
Table 1: Location of RT-PCR primers
Single exon dup1 Forward 1 Reverse 1 Forward 2 Reverse 2
Dup exon 44 Exon 41 Exon 47 Exon 42 Exon 45
Dup exon 45 Exon 43 Exon 48 Exon 44 Exon 47
Multiexon dup
Original exon 52 Exon 50 Exon 54 Exon 51 Exon 53
Duplicated exon 52 Exon 63 Exon 54 Exon 63 Exon 53
Original exon 62 Exon 60 Exon 63 Exon 61 Exon 63
Duplicated exon 62 Exon 60 Exon 66 Exon 61 Exon 65
3' dup breakpoint Exon 60 Exon 54 Exon 61 Exon 53
Across dup Exon 63 Exon 66 Exon 63 Exon 65
1Dup = duplication
Schematic overview of the exon 52–62 duplication Figure 4
Schematic overview of the exon 52–62 duplication. Original and duplicated exons are shown in blue and red, respectively. The 
exon 52–62 duplication is located between exons 63 and 64 and therefore only the multiexon skip of the duplicated exons will 
restore the wild type transcript, whereas multiexon skipping of the original exon 52–62 will result in out-of-frame transcripts 
(upper and lower panel, respectively). Restoration of the reading frame can be achieved by skipping the duplicated exons 52 
and 62, or the original exons 62, 63 combined with the duplicated exons 52 and 62 (middle panel). Note that skipping of the 
original exon 52 or exon 62 disrupts the open-reading-frame (lower panel).BMC Medical Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2350/8/43
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type dystrophin after AON treatment. On the other hand,
for two exon 44 duplication patients, exon 44 skipping
turned out to be so efficient that mainly transcripts were
generated in which both duplicated exons were skipped.
Under suboptimal transfection conditions we observed
no skip at all. We note that exon 44 skipping has consist-
ently been very efficient in both patient and control cell
lines [6,13] and unpublished results], which might
explain why under optimal conditions both exons were
skipped in these exon 44 duplicated cells. This phenome-
non has never been observed for the exon 45 duplication.
Here, we mainly observed single exon 45 skipping after
AON treatment, regardless of whether the AON induced
very efficient (> 80% skipping levels as determined with
the Agilent lab on a chip system) or less efficient exon 45
skipping (~10% skipping levels) in control myotube cul-
tures. This suggests that the occurrence of single or double
exon skipping in single exon duplications is dependent on
the duplicated exon itself. Splicing of individual exons is
influenced by various exonic and intronic splicing
enhancers and silencers. Some exons are more dependent
of such regulatory elements than others for proper inclu-
sion in the mRNA, explaining why different duplicated
exons respond differently to AON treatment. Finally, skip-
ping efficiency may even be different for unrelated
patients carrying the 'same' single exon duplication as the
intronic breakpoints (and thus the presence or absence of
intronic enhancers) may vary.
Multiple exon duplications are more challenging, as the
normal transcript can only be restored by multiexon skip-
ping, which is less efficient than single exon skipping and
not feasible for each and every stretch of exons [12]. Alter-
natively, the reading frame of the duplication can be
restored by targeting a smaller amount of duplicated
exons. The difficulty is that in addition to the targeted
exon (the skipping of which will restore the open reading
frame) there is another similar exon, for which the skip-
ping is frame-disrupting. It may be hard to identify which
of these exons are skipped. In addition, the analysis may
be obscured due to PCR artefacts. As both the original and
the duplicated part of the transcript are similar to each
other, they can anneal and give rise to products that are
similar to 'wild type' fragments. It should be noted that we
observed these seemingly normal fragments in non
treated RNA samples for each patient. For the single exon
duplication, there are no exon junctions in the restored
transcript that are not also present in the duplicated tran-
script. Thus it is impossible to perform a PCR specific for
the skipped RNAs and so discriminate between artefacts
and skipped fragments. However, in line with the severity
of the disease, no dystrophin was detected in untreated
samples. Due to the nature of the duplication (exon 52–
62 located between exon 63 and exon 64), we could dis-
criminate between artefacts and restored fragments using
Exon skipping in myotube cultures from a patient with an  exon 52–62 duplication Figure 5
Exon skipping in myotube cultures from a patient with an 
exon 52–62 duplication. A-F. RT-PCR analysis. After treat-
ment (+) specific skipping of the original and the duplicated 
exons 52 and 62 was induced in patient myotubes, while 
these skips were not found before treatment (-) (A-D). Since 
the duplicated exons are located between exon 63 and 64, 
the patient appears to have an exon 63 deletion using prim-
ers flanking this exon (D). Skipping of the original exons 62, 
63, and the duplicated exon 52 could be detected at low lev-
els in untreated myotube cultures (E). After AON treatment, 
these levels increased and, in addition, single exon 62 skip-
ping was induced. Primers specific for the duplication (B and 
E) generated only non specific fragments in the control sam-
ple, as confirmed by sequencing analysis (C). Using primers 
flanking the duplication (F) normally spliced transcripts were 
detected both in untreated and treated patient RNA, albeit 
at lower levels than the control. The expected fragment of 
~1900 bp containing the duplication was not observed 
(upper marker band is 2 kb). In-frame and out-of-frame tran-
scripts are shown in green and red, respectively. Duplicated 
exons are shaded in blue. M is 100 bp DNA size marker, -RT 
is negative control. G. Western blot analysis. No dystrophin 
could be detected in protein isolated from untreated (NT) 
myotubes, or from myotubes isolated 1, 4 and 8 days after 
AON treatment. A clear dystrophin signal (dy4) is present in 
protein isolated from unaffected control myotube cultures 
(C) (diluted 1:15 to prevent overexposure). Myosin (MF20) 
signals could be detected in both treated and untreated 
patient samples, indicating that the differentiation stage of the 
myotubes was sufficient to allow dystrophin synthesis.BMC Medical Genetics 2007, 8:43 http://www.biomedcentral.com/1471-2350/8/43
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primers in exon 63. Surprisingly, wild type fragments were
observed both in treated and untreated samples, albeit at
low levels. As not a hint of dystrophin could be observed
on the Western blot, these levels are not sufficient to gen-
erate detectable amounts of protein. Thus, novel expres-
sion of the dystrophin protein can here be used as
outcome measurement to assess whether the reading
frame is restored for multiple exon duplications. The
resulting dystrophin would likely be functional, as BMD
patients with in-frame duplications have been reported.
However, it cannot be excluded that the additional
domains encoded by the duplicated exons may disrupt
the secondary structure of the protein as there are DMD
patients carrying in-frame duplications as well [5].
The multiexon duplication patient in this study was extra
challenging, since the duplicated exons 52–62 are not
located between exons 62 and 63, but between exons 63
and 64 [18]. Therefore, even though we were unable to
restore dystrophin for this particular patient, other multi-
exon duplications may be easier to correct, especially
those involving only a limited number of exons.
Conclusion
Exon skipping for patients with small duplications offers
an ideally therapeutic approach, as it allows the restora-
tion of the wild type transcript. Indeed we here achieved
this by skipping a single copy of exon 45. If the skipping
is too rigorous, multiexon skipping including adjacent
exons can alternatively be applied to restore the open
reading frame, achieving a BMD-like restoration product
similar to those obtained after the correction of out-of-
frame deletions. For larger multi-exon duplications resto-
ration of the wild type transcript and/or the reading frame
is more challenging and its achievement will depend on
the nature and the number of exons duplicated.
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